CVRx Enrolls First Patient in BENEFIT-HF Heart Failure Trial Testing Barostim Device

Key Takeaways

• CVRx has enrolled the first patient in its pivotal BENEFIT-HF clinical trial evaluating the Barostim neuromodulation device for heart failure treatment
• The trial represents a significant expansion of the patient population eligible for Barostim therapy beyond current indications
• BENEFIT-HF is expected to become one of the largest therapeutic cardiac device trials, potentially supporting broader FDA approval

---

CVRx, Inc. (NASDAQ: CVRX) announced the enrollment of the first patient in its landmark BENEFIT-HF clinical trial on May 4, 2026, marking a significant milestone for the company’s Barostim neuromodulation device in heart failure treatment.

The enrollment took place at North Central Heart, a division of Avera Heart Hospital in Sioux Falls, South Dakota, under the supervision of Dr. Orvar Jonsson. This pivotal trial represents CVRx’s most ambitious study to date for its Barostim technology.

Expanding Treatment Options for Heart Failure

The BENEFIT-HF trial is designed to evaluate Barostim’s effectiveness in a significantly expanded heart failure patient population compared to current approved indications. Barostim is a neuromodulation device that stimulates the carotid baroreceptors to help regulate cardiovascular function.

CVRx, a Minneapolis-based medical device company, specializes in developing innovative neuromodulation solutions for cardiovascular diseases. The company’s Barostim device is already approved for certain heart failure patients, but this trial could potentially broaden its therapeutic reach.

IntelligenceRegulatory Impact▾

EMA and MHRA are the agencies to watch. Regulatory relevance reads medium for pharmaceutical intelligence. Teams should track submission types, designations, and guidance shifts that could move approval timelines.

Market Impact and Clinical Significance

The BENEFIT-HF trial is positioned to become one of the largest therapeutic cardiac device studies ever conducted. Success in this trial could significantly expand CVRx’s addressable market and provide new treatment options for heart failure patients who currently have limited therapeutic alternatives.

Heart failure affects millions of patients worldwide, with many experiencing inadequate symptom control despite optimal medical therapy. Neuromodulation approaches like Barostim offer a novel mechanism of action that could complement existing treatments.

IntelligenceCompetitive Intelligence▾

Competitive pressure is low. Watch which sponsors move first. Benchmark pipeline positioning, differentiation, and partnership scouting against the signals in this story.

Looking Forward

The initiation of patient enrollment represents a critical step toward potentially expanding Barostim’s clinical applications. The trial’s results could influence future regulatory submissions and market adoption of the technology across a broader patient population.

---

Frequently Asked Questions

What is the Barostim device and how does it work?

Barostim is a neuromodulation device that stimulates carotid baroreceptors to help regulate cardiovascular function and improve heart failure symptoms through the body’s natural regulatory mechanisms.

When will results from the BENEFIT-HF trial be available?

While specific timelines weren’t disclosed, large cardiac device trials typically take 2-4 years to complete enrollment and follow-up, with preliminary results potentially available in 2028-2030.

How does this trial differ from previous Barostim studies?

BENEFIT-HF evaluates Barostim in a significantly expanded heart failure patient population beyond current approved indications, potentially making the therapy available to more patients if successful.

Related coverage

• Quoin Pharmaceuticals Aims for First Peeling Skin Syndrome Trial with FDA IND Submission
• New EU Template for Clinical Trial Recruitment and Informed Consent: What Pharma Teams Need to Know
• Myasthenia Gravis Clinical Trial Pipeline Expands as 25+ Companies Race to Redefine Myasthenia Gravis Treatment Landscape | DelveInsight — regulatory updates